Financhill
Sell
48

HSIC Quote, Financials, Valuation and Earnings

Last price:
$64.44
Seasonality move :
5.27%
Day range:
$63.69 - $65.56
52-week range:
$60.56 - $82.49
Dividend yield:
0%
P/E ratio:
21.37x
P/S ratio:
0.66x
P/B ratio:
2.38x
Volume:
1.1M
Avg. volume:
1.3M
1-year change:
-6.28%
Market cap:
$8.1B
Revenue:
$12.7B
EPS (TTM):
$3.04

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HSIC
Henry Schein
$3.2B $1.11 2.15% 57.25% $77.17
AIMD
Ainos
-- -- -- -- --
INBS
Intelligent Bio Solutions
$1.4M -- 160.36% -- --
LAB
Standard BioTools
$40.1M -$0.04 -11.95% -85.19% $2.38
LNSR
LENSAR
$13.4M -$0.16 26.61% -18.42% $15.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HSIC
Henry Schein
$64.97 $77.17 $8.1B 21.37x $0.00 0% 0.66x
AIMD
Ainos
$0.55 -- $8.4M -- $0.00 0% 56.72x
INBS
Intelligent Bio Solutions
$1.28 -- $6.8M -- $0.00 0% 1.47x
LAB
Standard BioTools
$1.11 $2.38 $420.7M -- $0.00 0% 2.25x
LNSR
LENSAR
$14.05 $15.00 $165.6M -- $0.00 0% 3.03x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HSIC
Henry Schein
42.77% 1.386 25.27% 0.57x
AIMD
Ainos
20.03% 0.661 81.11% 0.22x
INBS
Intelligent Bio Solutions
8.5% 2.715 6.18% 0.66x
LAB
Standard BioTools
0.06% -0.535 0.05% 4.95x
LNSR
LENSAR
-- 1.470 -- 1.93x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HSIC
Henry Schein
$993M $192M 5.21% 7.8% 5.05% $159M
AIMD
Ainos
$80 -$4.6M -45.16% -52.95% -15756.26% -$865.1K
INBS
Intelligent Bio Solutions
$223.1K -$2.3M -152.69% -164.63% -369.27% -$2.3M
LAB
Standard BioTools
$21.9M -$29.7M -32.61% -36.54% -64.16% -$17.4M
LNSR
LENSAR
$7.1M -$1.3M -134.77% -134.77% -7.71% $3.7M

Henry Schein vs. Competitors

  • Which has Higher Returns HSIC or AIMD?

    Ainos has a net margin of 2.95% compared to Henry Schein's net margin of -15991.17%. Henry Schein's return on equity of 7.8% beat Ainos's return on equity of -52.95%.

    Company Gross Margin Earnings Per Share Invested Capital
    HSIC
    Henry Schein
    31.12% $0.74 $7.4B
    AIMD
    Ainos
    -29.07% -$0.30 $28.4M
  • What do Analysts Say About HSIC or AIMD?

    Henry Schein has a consensus price target of $77.17, signalling upside risk potential of 18.79%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that Henry Schein has higher upside potential than Ainos, analysts believe Henry Schein is more attractive than Ainos.

    Company Buy Ratings Hold Ratings Sell Ratings
    HSIC
    Henry Schein
    3 9 1
    AIMD
    Ainos
    0 0 0
  • Is HSIC or AIMD More Risky?

    Henry Schein has a beta of 0.871, which suggesting that the stock is 12.861% less volatile than S&P 500. In comparison Ainos has a beta of 2.137, suggesting its more volatile than the S&P 500 by 113.734%.

  • Which is a Better Dividend Stock HSIC or AIMD?

    Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HSIC or AIMD?

    Henry Schein quarterly revenues are $3.2B, which are larger than Ainos quarterly revenues of $20.7K. Henry Schein's net income of $94M is higher than Ainos's net income of -$4.7M. Notably, Henry Schein's price-to-earnings ratio is 21.37x while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.66x versus 56.72x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HSIC
    Henry Schein
    0.66x 21.37x $3.2B $94M
    AIMD
    Ainos
    56.72x -- $20.7K -$4.7M
  • Which has Higher Returns HSIC or INBS?

    Intelligent Bio Solutions has a net margin of 2.95% compared to Henry Schein's net margin of -370.29%. Henry Schein's return on equity of 7.8% beat Intelligent Bio Solutions's return on equity of -164.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    HSIC
    Henry Schein
    31.12% $0.74 $7.4B
    INBS
    Intelligent Bio Solutions
    36.73% -$0.50 $4.6M
  • What do Analysts Say About HSIC or INBS?

    Henry Schein has a consensus price target of $77.17, signalling upside risk potential of 18.79%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 837.5%. Given that Intelligent Bio Solutions has higher upside potential than Henry Schein, analysts believe Intelligent Bio Solutions is more attractive than Henry Schein.

    Company Buy Ratings Hold Ratings Sell Ratings
    HSIC
    Henry Schein
    3 9 1
    INBS
    Intelligent Bio Solutions
    0 0 0
  • Is HSIC or INBS More Risky?

    Henry Schein has a beta of 0.871, which suggesting that the stock is 12.861% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HSIC or INBS?

    Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HSIC or INBS?

    Henry Schein quarterly revenues are $3.2B, which are larger than Intelligent Bio Solutions quarterly revenues of $607.5K. Henry Schein's net income of $94M is higher than Intelligent Bio Solutions's net income of -$2.2M. Notably, Henry Schein's price-to-earnings ratio is 21.37x while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.66x versus 1.47x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HSIC
    Henry Schein
    0.66x 21.37x $3.2B $94M
    INBS
    Intelligent Bio Solutions
    1.47x -- $607.5K -$2.2M
  • Which has Higher Returns HSIC or LAB?

    Standard BioTools has a net margin of 2.95% compared to Henry Schein's net margin of -72.93%. Henry Schein's return on equity of 7.8% beat Standard BioTools's return on equity of -36.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    HSIC
    Henry Schein
    31.12% $0.74 $7.4B
    LAB
    Standard BioTools
    46.89% -$0.09 $472M
  • What do Analysts Say About HSIC or LAB?

    Henry Schein has a consensus price target of $77.17, signalling upside risk potential of 18.79%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 113.96%. Given that Standard BioTools has higher upside potential than Henry Schein, analysts believe Standard BioTools is more attractive than Henry Schein.

    Company Buy Ratings Hold Ratings Sell Ratings
    HSIC
    Henry Schein
    3 9 1
    LAB
    Standard BioTools
    2 1 0
  • Is HSIC or LAB More Risky?

    Henry Schein has a beta of 0.871, which suggesting that the stock is 12.861% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.804, suggesting its more volatile than the S&P 500 by 80.443%.

  • Which is a Better Dividend Stock HSIC or LAB?

    Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HSIC or LAB?

    Henry Schein quarterly revenues are $3.2B, which are larger than Standard BioTools quarterly revenues of $46.7M. Henry Schein's net income of $94M is higher than Standard BioTools's net income of -$34.1M. Notably, Henry Schein's price-to-earnings ratio is 21.37x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.66x versus 2.25x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HSIC
    Henry Schein
    0.66x 21.37x $3.2B $94M
    LAB
    Standard BioTools
    2.25x -- $46.7M -$34.1M
  • Which has Higher Returns HSIC or LNSR?

    LENSAR has a net margin of 2.95% compared to Henry Schein's net margin of -111.78%. Henry Schein's return on equity of 7.8% beat LENSAR's return on equity of -134.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    HSIC
    Henry Schein
    31.12% $0.74 $7.4B
    LNSR
    LENSAR
    42.48% -$1.61 $4.9M
  • What do Analysts Say About HSIC or LNSR?

    Henry Schein has a consensus price target of $77.17, signalling upside risk potential of 18.79%. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 6.76%. Given that Henry Schein has higher upside potential than LENSAR, analysts believe Henry Schein is more attractive than LENSAR.

    Company Buy Ratings Hold Ratings Sell Ratings
    HSIC
    Henry Schein
    3 9 1
    LNSR
    LENSAR
    0 2 0
  • Is HSIC or LNSR More Risky?

    Henry Schein has a beta of 0.871, which suggesting that the stock is 12.861% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock HSIC or LNSR?

    Henry Schein has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Henry Schein pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HSIC or LNSR?

    Henry Schein quarterly revenues are $3.2B, which are larger than LENSAR quarterly revenues of $16.7M. Henry Schein's net income of $94M is higher than LENSAR's net income of -$18.7M. Notably, Henry Schein's price-to-earnings ratio is 21.37x while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Henry Schein is 0.66x versus 3.03x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HSIC
    Henry Schein
    0.66x 21.37x $3.2B $94M
    LNSR
    LENSAR
    3.03x -- $16.7M -$18.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 37x

Alerts

Sell
50
RGC alert for May 1

Regencell Bioscience Holdings [RGC] is up 20.58% over the past day.

Sell
38
WGS alert for May 1

GeneDx Holdings [WGS] is down 6.85% over the past day.

Sell
43
VICR alert for May 1

Vicor [VICR] is down 1.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock